CTOs on the Move


 
Tripos, L.P. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.tripos.com
  • 1699 S Hanley Rd
    Saint Louis, MO USA 63144
  • Phone: 314.647.1099

Executives

Name Title Contact Details

Similar Companies

Phycotransgenics

Phycotransgenics is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alucent Biomedical

Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.

Cidara

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.

Synecor

Synecor is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.